FMP
Geron Corporation
GERN
NASDAQ
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
3.3 USD
-0.0424 (-1.29%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. John A. Scarlett M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.geron.comexchange
NASDAQ
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
CIK
0000886744
ISIN
US3741631036
CUSIP
374163103
Address
919 East Hillsdale Boulevard
Phone
650 473 7700
Country
US
Employee
141
IPO Date
Jul 31, 1996
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
GERN Financial Summary
CIK
0000886744
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
374163103
ISIN
US3741631036
Country
US
Price
3.3
Beta
0.52
Volume Avg.
8.46M
Market Cap
1.99B
Shares
-
52-Week
1.64-5.34
DCF
-0.03
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-10.3
P/B
-
Website
https://www.geron.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GERN News
It looks like there's no news available.
